The goal of this study is to evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice.Macular edema is a major complication of several vascular and inflammatory retinal diseases Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). This study was conducted on 30 patients with retinal vein occlusion  .The study population were also randomly assigned into two groups regarding the management regimens: 15 subjects as central RVO ,15 subjects as branch RVO. Recently, antiangiogenic therapy with anti-vascular endothelialyy growth factor (anti-VEGF) has been used successfully to treat MO resulting from a variety of causes. As elevated intraocular levels of VEGF have been demonstrated in patients with retinal vein occlusions there is a strong basis for the hypothesis that anti-VEGF agents may be beneficial in the treatment of vascular leakage and MO.